Table 5.
Serum EIMD markers of triathletes at T1 and T2 (after 9 weeks).
| Group | T1 | T2 | p (T × G) | η2p |
|---|---|---|---|---|
| Urea (mg/dL) | ||||
| PLG | 37.38 ± 6.63 | 38.00 ± 4.81 | 0.260 | 0.131 |
| CITG | 37.06 ± 6.92 | 34.58 ± 8.72 | ||
| BRG | 38.38 ± 4.03 | 37.50 ± 2.83 | ||
| CIT + BRG | 36.75 ± 8.55 | 41.13 ± 6.06 | ||
| Creatinine (mg/dL) | ||||
| PLG | 0.91 ± 0.10 | 0.92 ± 0.10 | 0.601 | 0.063 |
| CITG | 0.93 ± 0.57 | 0.92 ± 0.11 | ||
| BRG | 0.92 ± 0.11 | 0.88 ± 0.09 | ||
| CIT + BRG | 0.91 ± 0.09 | 0.91 ± 0.11 | ||
| AST (UI/L) | ||||
| PLG | 33.50 ± 9.06 | 37.13 ± 16.31 | 0.321 | 0.115 |
| CITG | 30.50 ± 9.09 | 24.38 ± 3.93 | ||
| BRG | 39.38 ± 17.39 | 29.36 ± 4.79 | ||
| CIT + BRG | 37.38 ± 12.02 | 29.75 ± 7.91 | ||
| ALT (UI/L) | ||||
| PLG | 28.00 ± 14.25 | 29.63 ± 13.76 | 0.327 | 0.114 |
| CITG | 25.88 ± 9.43 | 22.00 ± 5.40 | ||
| BRG | 36.25 ± 29.36 | 23.38 ± 8.45 | ||
| CIT + BRG | 33.25 ± 19.83 | 22.63 ± 7.65 | ||
| GGT (UI/L) | ||||
| PLG | 16.88 ± 4.55 | 18.50 ± 6.37 | 0.699 | 0.049 |
| CITG | 18.88 ± 8.04 | 19.88 ± 8.94 | ||
| BRG | 15.50 ± 3.46 | 18.63 ± 6.41 | ||
| CIT + BRG | 19.75 ± 5.92 | 20.25 ± 8.78 | ||
| LDH (UI/L) | ||||
| PLG | 438.86 ± 48.13 | 367.38 ± 77.77 | 0.498 | 0.083 |
| CITG | 330.88 ± 90.99 a | 324.00 ± 71.97 | ||
| BRG | 445.38 ± 247.59 b | 393.88 ± 35.79 * | ||
| CIT + BRG | 431.00 ± 75.05 | 411.88 ± 63.37 | ||
| CK (UI/L) | ||||
| PLG | 319.50 ± 297.34 | 175.00 ± 51.77 | 0.238 | 0.138 |
| CITG | 327.63 ± 287.07 | 157.25 ± 60.78 | ||
| BRG | 328.38 ± 247.59 | 208.88 ± 98.22 | ||
| CIT + BRG | 379.38 ± 336.75 | 288.25 ± 209.86 | ||
Data are presented as mean ± standard deviation. p (T × G): interaction group-by-time (p < 0.05) by two-way repeated-measures ANOVA. *: Significant differences between the two phases (T1 vs. T2) (p < 0.05). a: Significant differences with respect to PLG (p < 0.05). b: Significant differences with respect to CITG (p < 0.05).